Erratum: Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types (Glycobiology (2007) vol. 17 (1) (104-188) 10.1093/glycob/cwl057);Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, hybrid, and complex types

Glycobiology

Volumn 17, Issue 1, 2007, Pages 104-118

  Kanda, Yutaka ^a   Yamada, Tsuyoshi ^a   Mori, Katsuhiro ^a   Okazaki, Akira ^a   Inoue, Miho ^a   Kitajima Miyama, Kazuko ^a   Kuni Kamochi, Reiko ^a   Nakano, Ryosuke ^a   Yano, Keiichi ^a   Kakita, Shingo ^a   Shitara, Kenya ^a   Satoh, Mitsuo ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1,6 FUCOSYLTRANSFERASE; ASPARAGINE LINKED OLIGOSACCHARIDE; CD20 ANTIBODY; COMPLEMENT COMPONENT C1Q; FC RECEPTOR; FUCOSE; FUCOSYLTRANSFERASE; IMMUNOGLOBULIN G1 ANTIBODY; KIFUNENSINE; MANNOSE; RITUXIMAB; SWAINSONINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CHO CELL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; FUCOSYLATION; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

CRICETULUS GRISEUS;

EID: 33845590523     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwm091     Document Type: Erratum

References (48)

1. Awwad M, Strome PG, Gilman SC, Axelrod HR. 1994. Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions. Cancer Immunol Immunother. 38:23-30.
2. Crispin M, Harvey DJ, Chang VT, Yu C, Aricescu AR, Jones EY, Davis SJ, Dwek RA, Rudd PM. 2006. Inhibition of hybrid- and complex-type glycosylation reveals the presence of the GlcNAc transferase I-independent fucosylation pathway. Glycobiology. 16:748-756.
3. Ferrara C, Brunker P, Suter T, Moser S, Puntener U, Umana P. 2006. Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and coexpression of heterologous β1,4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II. Biotechnol Bioeng. 93:851-861.
4. Ferrara C, Stuart F, Sondermann P, Brunker P, Umana P. 2006. The carbohydrate at FcγRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem. 281: 5032-5036.
5. Harada H, Kamei M, Tokumoto Y, Yui S, Koyama F, Kochibe N, Endo T, Kobata A. 1987. Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns. Anal Biochem. 164:374-381.
6. Harris LJ, Skaletsky E, Mcpherson A. 1998. Crystallographic structure of an intact IgG1 monoclonal antibody. J Mol Biol. 275:861-872.
7. Huber R, Deisenhofer J, Colman PM. 1976. Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature. 264:415-420.
8. Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M. 2006. Non-fucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcγRIIIa. Clin Cancer Res. 12:2879-2887.
9. Jefferis R. 2002. Glycosylation of human IgG antibodies: Relevance to therapeutic applications. BioPharm. 14:19-26.
10. Jefferis R. 2005. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog. 21:11-16.
11. Jefferis R, Lund J. 2002. Interaction sites on human IgG-Fc for FcγR: current models. Immunol Lett. 82:57-65.
12. Jefferis R, Lund J, Pound J. 1998. IgG-Fc mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev. 163:59-76.
13. Junghans RP, Anderson CL. 1996. The protection receptor for IgG catabolism is the β2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA. 93:5512-5516.
14. Kamoda S, Nomura C, Kinoshita M, Nishiura S, Ishikawa R, Kakehi K, Kawasaki N, Hayakawa T. 2004. Profiling analysis of oligosaccharides in antibody pharmaceuticals by capillary electrophoresis. J Chromatogr A. 1050:211-216.
15. Kanda Y, Yamane-Ohnuki N, Sakai N, Yamano K, Nakano R, Inoue M, Misaka H, Iida S, Wakitani M, Konno Y et al. 2006. Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol Bioeng. 94:680-688.
16. Lin AI, Philipsberg GA, Haltiwanger RS. 1994. Core fucosylation of highmannose- type oligosaccharides in GlcNAc transferase I-deficient (Lec1) CHO cells. Glycobiology. 4:895-901.
17. Malaise MG, Hoyoux C, Franchimont P, Mahieu PR. 1990. Evidence for a role of accessible galactosyl or mannosyl residues of Fc domain in the in vivo clearance of IgG antibody-coated autologous erythrocytes in the rat. Clin Immunol Immunopathol. 54:469-483.
18. Mizuochi T, Taniguchi T, Shimizu A. 1982. Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. J Immunol. 129: 2016-2020.
19. Mori K, Kuni-Kamochi R, Yamane-Ohnuki N, Wakitani M, Yamano K, Imai H, Kanda Y, Niwa R, Iida S, Uchida K et al. 2004. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng. 88:901-908.
20. Nakamura K, Tanaka Y, Fujino I, Hirayama N, Shitara K, Hanai N. 2000. Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody. Mol Immunol. 37: 1035-1046.
21. Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K. 2005. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. J Immunol Methods. 306:93-103.
22. Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K. 2004. Enhancement of the antibodydependent cellular cytotoxicity of low-fucose IgG1 is independent of FcγRIIIa functional polymorphism. Clin Cancer Res. 10:6248-6255.
23. Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K. 2005. IgG subclass-independent improvement of antibodydependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods. 306:151-160.
24. Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, Nakamura K, Shitara K. 2005. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res. 11:2327-2336.
25. Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K. 2004. Defucosylated anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T cell leukemia and lymphoma. Cancer Res. 64:2127-2133.
26. Nose M, Heyman B. 1990. Inhibition of processing of asparagine-linked carbohydrate chains on IgG2a by using swainsonine has no influence upon antibody effector functions in vitro. J Immunol. 145:910-914.
27. Ober J, Martinez C, Lai X, Zhou J, Ward S. 2004. Exocytosis of IgG as mediated by the receptor, FcRn: An analysis at the single-molecule level. Proc Natl Acad Sci USA. 101:11076-11081.
28. Ohta S, Honda A, Tokutake Y, Yoshida H, Hanai N. 1993. Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3. Cancer Immunol Immunother. 36:260-266.
29. Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K. 2004. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcγRIIIa. J Mol Biol. 336:1239-1249.
30. Papac I, Briggs B, Chin T, Jones J. 1998. A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis. Glycobiology. 8:445-454.
31. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. 2001. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem. 276:16469-16477.
32. Rademacher TW, Parekh RB, Dwek RA. 1988. Glycobiology. Annu Rev Biochem. 57:785-838.
33. Ripka J, Adamany A, Stanley P. 1986. Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose. Arch Biochem Biophys. 249:533-545.
34. Rothman J, Perussia B, Herlyn D, Warren L. 1989. Antibody-dependent cytotoxicity mediated by natural killer cells is enhanced by castanospermine-induced alterations of IgG glycosylation. Mol Immunol. 26:1113-1123.
35. Schenerman MA, Hope JN, Kletke C, Singh JK, Kimura R, Tsao EI, Folena-Wasserman G. 1999. Comparability testing of a humanized monoclonal antibody (synagis) to support cell line stability, process validation, and scale-up for manufacturing. Biologicals. 27:203-215.
36. Schuster M, Umana P, Ferrara C, Brunker P, Gerdes C, Waxenecker G, Wiederkum S, Schwager C, Loibner H, Himmler G et al. 2005. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res. 65:7934-7941.
37. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J Biol Chem. 277:26733-26740.
38. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M et al. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 278:3466-3473.
39. Stanley P, Chaney W. 1985. Control of carbohydrate processing: The lec1A CHO mutation results in partial loss of N-acetylglucosaminyltransferase I activity. Mol Cell Biol. 5:1204-1211.
40. Tao MH, Smith RI, Morrison SL. 1993. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med. 178:661-667.
41. Thornburg RW, Day JF, Baynes JW, Thorpe SR. 1980. Carbohydrate-mediated clearance of immune complexes from the circulation. A role for galactose residues in the hepatic uptake of IgG-antigen complexes. J Biol Chem. 255:6820-6825.
42. Uozumi N, Yanagidani S, Miyoshi E, Ihara Y, Sakuma T, Gao CX, Teshima T, Fujii S, Shiba T, Taniguchi N. 1996. Purification and cDNA cloning of porcine brain GDP-L-Fuc:N-acetyl-β-D-glucosaminide α1,6-fucosyltransferase. J Biol Chem. 271:27810-27817.
43. Urlaub G, Chasin LA. 1980. Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc Natl Acad Sci USA. 77: 4216-4220.
44. H2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med. 180:1087-1096.
45. Wright A, Morrison SL. 1998. Effect of C2-associated carbohydrate structure on Ig effector function: Studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol. 160:3393-3402.
46. Wright A, Sato Y, Okada T, Chang K, Endo T, Morrison S. 2000. In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology. 10:1347-1355.
47. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K et al. 2004. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng. 87:614-622.
48. Yanagidani S, Uozumi N, Ihara Y, Miyoshi E, Yamaguchi N, Taniguchi N. 1997. Purification and cDNA cloning of GDP-L-Fuc:N-acetyl-beta-A-glucosaminide: alpha1-6 fucosyltransferase (alpha1-6 FucT) from human gastric cancer MKN45 cells. J Biochem (Tokyo). 121: 626-632.